BioInvent has released additional positive preliminary efficacy data from its ongoing phase IIa dose expansion study of BI-1808 as a monotherapy. Additionally, BioInvent and Transgene are set to present encouraging initial phase I/IIa data on BT-001 at ESMO 2024. BI-1910 will also be featured in a poster presentation at the same conference.

Read the article at biostock.se:

https://www.biostock.se/en/2024/09/bioinvent-makes-a-strong-entrance-at-esmo-in-barcelona/

This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se/